Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Share-based Compensation (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Share-based Compensation for 9 consecutive years, with $373000.0 as the latest value for Q4 2024.

  • Quarterly Share-based Compensation fell 24.95% to $373000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2024, down 25.31% year-over-year, with the annual reading at $2.0 million for FY2025, 25.06% up from the prior year.
  • Share-based Compensation for Q4 2024 was $373000.0 at SELLAS Life Sciences, down from $381000.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $543000.0 in Q3 2023, with the low at $141000.0 in Q4 2020.
  • Average Share-based Compensation over 5 years is $348650.0, with a median of $374000.0 recorded in 2022.
  • The sharpest move saw Share-based Compensation skyrocketed 104.26% in 2021, then crashed 35.02% in 2024.
  • Over 5 years, Share-based Compensation stood at $141000.0 in 2020, then skyrocketed by 104.26% to $288000.0 in 2021, then soared by 54.86% to $446000.0 in 2022, then increased by 11.43% to $497000.0 in 2023, then fell by 24.95% to $373000.0 in 2024.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $373000.0, $381000.0, and $334000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.